Onyx keeps neutral rating from Merrill

Onyx Pharmaceuticals, Inc. was maintained at neutral by Merrill Lynch analyst Eric Ende. Both

Onyx and Bayer have fully enrolled their phase 3 liver and melanoma studies for Nexavar. Positive data in melanoma and liver cancer during the second half of the year could offset potentially increased Sutent competition. While first-quarter 2006 Nexavar sales of $24 million were positive, Merrill believes Nexavar could trade front-line market share for second-line share. Shares of the Emeryville, Calif., biopharmaceutical company were down $0.22, or 0.96%, at $22.72 on volume of 719,167 shares versus the three-month running average of 610,008 shares. (Nasdaq: ONXX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.